Health In Tech, Inc. Class A ((HIT)) has held its Q1 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Health In Tech, Inc. struck an ambivalent tone on its latest earnings call, pairing upbeat product and technology momentum with clear near-term financial strain. Management highlighted robust platform innovation, new KPIs, and a sizable market opportunity, yet rising operating expenses and negative profitability, plus mixed signals on 2026 revenue guidance, left investors weighing growth potential against execution and visibility risks.
Revenue Growth and Full-Year Guidance
Health In Tech reported Q1 2026 revenue of $8.8 million, up about 9% year over year, signaling steady but not hypergrowth. Management nonetheless reaffirmed an aggressive full-year 2026 revenue target of $45 million to $50 million, implying roughly 35% to 50% growth versus 2025 and putting significant pressure on the remainder of the year.
PPPV and Contracted Revenue Add Visibility
The company introduced Platform Placed Plan Value (PPPV), disclosing that $82 million of self-funded stop-loss plans were placed through its platform in Q1 2026. It also reported $22.9 million of contracted revenue still to be recognized over the rest of 2026, giving investors a clearer line of sight into future reported revenue tied to existing business.
Building on a Strong 2025 Revenue Base
Management emphasized that 2025 revenue reached $33 million, achieved with only six in-house sales representatives. This prior-year performance serves as a reference point for scale and suggests that modest headcount additions and deeper channel penetration could support the ambitious 2026 revenue aspirations.
Platform Upgrades Win Broker Approval
Health In Tech rolled out major enhancements to its eDIYBS platform, including a refreshed user interface, better workflows, and improved census insights for brokers. Early feedback has been positive, with brokers citing meaningful workflow efficiency gains from features such as large-group quoting improvements, automated document upload, and AI-driven risk insights.
New Products and Strategic Pilots Broaden Offering
The company launched enhanced self-funded plan administration built around more than 100 pre-configured plan bundles, aiming to simplify plan design and deployment. It also announced a three-year rate stabilization program and a planned Q2 2026 beta for a data-driven solution that integrates psychological and claims data, positioning the platform for differentiated risk management.
Technology Partnerships and Architecture Overhaul
To accelerate its tech roadmap, Health In Tech engaged Ciklum, an AWS advanced tier partner, to bolster both front-end and back-end capabilities plus data infrastructure. A new chief technology officer with experience at SAP and IBM will lead next-generation architecture and AI underwriting initiatives, underscoring the company’s commitment to scalable, modern infrastructure.
Capital Raise Strengthens Liquidity
The company completed a private investment in public equity in March 2026, raising about $7 million in gross proceeds. Health In Tech ended Q1 with $10.3 million in cash and equivalents, providing a buffer to support ongoing product development, distribution expansion, and technology investments despite current operating losses.
New KPIs Improve Reporting Transparency
Management introduced contracted revenue and PPPV as key performance indicators, moving away from the enrolled-employee metric that had been less reflective of plan complexity and value. These new disclosures are designed to better capture the economic scale of plans placed on the platform and to offer investors a clearer picture of forward revenue visibility.
Profitability Slides into the Red
Adjusted EBITDA fell to negative $1.3 million in Q1 2026 from positive $1.2 million a year earlier, a swing of $2.5 million into loss territory. Net results followed a similar pattern, moving from $0.5 million of net income in the prior-year quarter to a $1.6 million net loss, as heavy investment outpaced modest revenue growth.
Operating Expenses Climb and Ratios Worsen
Total operating expenses rose to $6.7 million in Q1, up roughly 36.7% from $4.9 million in the year-ago period. As a percentage of revenue, operating costs jumped from about 41% to 76%, signaling that management is front-loading spending to build scale but also compressing margins in the short term.
Sales and Marketing Spend Surges
Sales and marketing expenses more than doubled to $2.3 million, representing about 26% of revenue versus 14% a year earlier. The company framed this jump as a deliberate investment to expand distribution and deepen broker relationships, though it weighs on near-term profitability and raises the stakes for execution.
R&D and Capitalized Software Pressure Margins
Research and development spending climbed to $0.9 million, about 10% of revenue, compared with $0.5 million and 7% of revenue a year earlier. Health In Tech also capitalized approximately $0.6 million of software development in Q1, indicating elevated technology spending that supports innovation but suppresses current reported earnings.
Guidance Consistency and Distribution Capacity Concerns
A key point of tension emerged when the CFO indicated that existing contracts plus Q1 revenue imply about $31.7 million of 2026 revenue, below the reiterated $45 million to $50 million guidance range. At the same time, management plans only modest sales headcount growth of two to three additional reps, which could slow broker onboarding and heighten execution risk around hitting the ambitious revenue targets.
Forward-Looking Outlook and Execution Risks
Management maintained its full-year 2026 revenue outlook of $45 million to $50 million, implicitly counting on strong second-half acceleration driven by new products, platform enhancements, and expanded distribution. However, the gap between contracted revenue and guidance, combined with rising costs and a slowly growing sales force, means investors will be watching closely for evidence that pipeline conversion and PPPV growth translate into reported revenue and improved profitability.
Health In Tech’s latest earnings call painted a story of a company investing aggressively to solidify its technology and product edge in self-funded health plans while accepting near-term financial pain. For investors, the key takeaway is that execution on distribution, contract conversion, and cost discipline will determine whether today’s platform gains and KPIs evolve into the revenue scale and margins implied by management’s 2026 targets.